

COMPANY STATEMENT

November 9, 2020

BD Statement on U.S. Needle and Syringe Availability

BD is committed to enabling health care providers to deliver patient care, which includes meeting critical needs for vaccinations. To ensure full transparency about product availability, below are the updates regarding the company's efforts at rapidly supplying vaccination needs for influenza, as well as meeting the U.S. government requirements for COVID-19 vaccine preparations.

Influenza vaccination efforts

In line with [CDC expectations](#) for a more robust 2020-21 influenza vaccination season, we are seeing a surge in demand for injection devices across U.S. health care providers. As a result, we are being challenged to increase our supply levels to match these market-wide needs.

BD remains intent on maintaining the continuity of supply of needles and syringes to our customers, and we are proud of our efforts to date:

- BD has produced and shipped the same volume of injection products as compared to the prior year period (exclusive of the U.S. government orders for COVID-19 vaccination efforts)
- We continue to produce at full capacity without disruption and are closely monitoring inventory and customer ordering to support supply continuity
- We have ensured stable and consistent supply output while also fulfilling U.S. government orders of COVID-19 injection devices

To help maintain a consistent supply of injection devices in the market, BD will:

- Continue to fulfill distributor orders aligned to historical purchase volumes;
- Provide support from our customer care teams for guidance on alternative solutions and devices, along with consistent updates on status of orders; and
- Activate additional sourcing from our global supply network and continue to accelerate ongoing capital investment and expansion across manufacturing plants to increase capacity and volume.

While we continue to meet overall demand for many of our products, we are experiencing tight supply in select product categories. We are proactively working with our channel partners and customers to address existing supply needs.

As these dynamics are creating tightness in supply across the industry, BD is reminding customers and channel partners of the important role they play in maintaining availability of injection devices for the greater public health need, including:

- Do not order quantities in excess of what is absolutely needed for current patient care;
- Do not stockpile devices or increase levels for par, on-hand inventory or allocation; and
- Do not "pull forward" orders that would typically be placed in the future.

COVID-19 vaccination efforts

Since July, we have provided regular customer updates regarding our support of the public-private partnership to supply injection devices for U.S. COVID-19 vaccine preparations.

Vaccine development is a rapidly evolving effort and BD continues to work closely with the U.S. government to make sure we are ready to support a full deployment when a vaccine is available. BD is actively producing and shipping product to supply nearly 286 million injection devices to the U.S. by Spring 2021.

With these efforts underway, BD is reminding customers and channel partners of the important role they play in maintaining availability of injection devices for the greater public health need, including:

- **There is no need for health care providers to order injection devices** in anticipation of administering this vaccine. Customers will be supplied needles and syringes to support their local COVID-19 vaccination efforts through the U.S. Health and Human Services (HHS) distribution plan.
- BD is not supplying health care providers, state or municipal government agencies or private entities in duplicative efforts of acquiring needles and syringes for the explicit use of administering COVID-19 vaccinations.
- BD is supplying injection devices for COVID-19 only for U.S. efforts outlined in the links below.

For more details about the availability and distribution of ancillary devices, please see these U.S. government resources:

- [COVID-19 Vaccination Program Interim Playbook](#)
- [The Operation Warp Speed Strategy for Distributing a COVID-19 Vaccine](#)

Collectively, our focus is to carefully plan supply capabilities to ensure maximum volumes can be dedicated to COVID-19 readiness efforts while minimizing disruption for routine health care and vaccination programs to support patient care needs.

Thank you for your continued support as we work together to respond to these urgent health care needs. BD's customer care and supply chain relations teams continue to be available to support customer needs and we will continue to provide regular updates at bd.com/COVID-19.